How Much Does Addyi (Flibanserin) Cost in Minnesota in 2026?

Brand-Name Addyi Pricing in Minnesota

The manufacturer list price for Addyi (flibanserin 100 mg) is $880 per month, and that figure holds across Minnesota retail pharmacies in 2026. A single prescription fills 30 tablets for nightly dosing. Without insurance or a discount card, this is the price a patient at CVS, Walgreens, or an independent pharmacy in Minneapolis, St. Paul, Duluth, or Rochester will encounter at the counter.

Sprout Pharmaceuticals, the company behind Addyi, has maintained this price point since the drug's FDA approval in August 2015. Unlike GLP-1 medications that have seen repeated list-price increases, Addyi's sticker price has remained flat. That stability has not, however, made the drug affordable for uninsured patients. The $880 monthly cost places it among the more expensive branded oral medications prescribed for women's sexual health.

Pharmacy markup in Minnesota is minimal for Addyi because the drug is distributed through a limited network. Patients who fill at pharmacies outside the preferred network may face the full list price without discount card eligibility. Checking with the prescribing provider or Sprout's patient support line before selecting a pharmacy can prevent surprise costs.

Minnesota Medicaid Coverage for Flibanserin

Minnesota Medicaid (Medical Assistance) does cover Addyi, but only with prior authorization. The PA requirement means a prescriber must submit clinical documentation showing the patient meets specific criteria before the state program will pay for the medication.

Typical PA criteria for flibanserin under Minnesota Medicaid include a confirmed diagnosis of hypoactive sexual desire disorder (HSDD) in a premenopausal woman, documentation that the low desire is not caused by a coexisting medical condition, a psychiatric disorder, a medication side effect, or relationship factors, and confirmation that the patient is not using the drug with alcohol (a boxed-warning contraindication from the FDA). Dr. Sheryl Kingsberg, a clinical psychologist and HSDD researcher at University Hospitals Cleveland Medical Center, has noted: "Prior authorization for HSDD treatments can delay care for weeks, and many women abandon the process before receiving medication."

PA turnaround times under Minnesota Medical Assistance typically range from 24 to 72 hours for standard requests. Urgent or expedited reviews can be completed within 24 hours if the prescriber marks the request accordingly. If a PA is denied, both the prescriber and the patient have the right to appeal through the Minnesota Department of Human Services fair hearing process.

Minnesota managed care organizations (MCOs) that administer Medicaid benefits, including UCare, Hennepin Health, and Blue Plus, may each apply slightly different PA templates. Prescribers should verify the specific MCO's formulary and PA form before submitting.

Commercial Insurance Coverage Across Minnesota

Most large commercial insurers in Minnesota place Addyi on their formulary, though nearly all require prior authorization or step therapy. Plans from Blue Cross Blue Shield of Minnesota, HealthPartners, Medica, and PreferredOne have covered flibanserin in recent plan years, though tier placement and copay amounts vary.

A patient on a preferred brand tier might pay $50 to $150 per month after PA approval. Those on a non-preferred or specialty tier could face $200 to $350 monthly. Self-funded employer plans, which are not regulated by state mandates, have the most variable coverage. Some exclude HSDD treatments entirely.

The Affordable Care Act does not specifically mandate coverage of HSDD medications. Minnesota state law has no standalone mandate requiring insurers to cover flibanserin either. Coverage decisions rest with individual plan formulary committees. Patients denied coverage can file an internal appeal and, if that fails, an external review through the Minnesota Department of Commerce.

One practical step: before the prescriber submits a PA, the patient should call the number on the back of their insurance card and ask three questions. Is flibanserin on formulary? What tier? What is the PA criteria document number? Having this information in advance allows the prescriber to tailor the PA submission to the plan's specific requirements, reducing denial rates.

Compounded Flibanserin in Minnesota

Compounded flibanserin is available in Minnesota through licensed 503A compounding pharmacies. These pharmacies prepare the drug from bulk pharmaceutical-grade flibanserin powder, producing capsules or suspensions that are functionally equivalent to brand-name Addyi but at a fraction of the cost.

Under federal law, 503A compounding pharmacies may prepare patient-specific prescriptions without FDA approval of the finished product, provided they operate under a valid prescription and comply with state board of pharmacy regulations. The Minnesota Board of Pharmacy licenses and inspects these facilities. Compounded flibanserin is legal in Minnesota when dispensed pursuant to a valid patient-specific prescription from a licensed prescriber.

Several telehealth platforms now offer compounded flibanserin to Minnesota residents at dramatically reduced prices. Some programs include the medication, prescriber consultation, and shipping for a flat monthly fee, bringing the effective cost to $0 out-of-pocket beyond the consultation fee. This pricing is possible because compounding pharmacies are not bound by the brand manufacturer's pricing structure.

Patients considering compounded flibanserin should verify that the pharmacy holds a current Minnesota 503A license, uses USP-grade raw materials, and performs potency and sterility testing on finished preparations. The American Society of Health-System Pharmacists recommends asking compounding pharmacies for their most recent inspection report and certificates of analysis for active ingredients.

The BEGONIA trial (N=1,087), published in the Journal of Sexual Medicine in 2014, demonstrated that flibanserin 100 mg at bedtime significantly increased the number of satisfying sexual events (SSEs) by 0.8 to 1.0 per month compared to placebo over 24 weeks (Katz et al., J Sex Med 2014). These efficacy data apply to the flibanserin molecule itself, not to a specific branded formulation, which supports the therapeutic rationale for compounded versions containing the same active ingredient at the same dose.

Telehealth Access to Addyi in Minnesota

Minnesota permits telehealth prescribing of flibanserin. No in-person visit is required. Premenopausal women across the state, from the Twin Cities metro to rural communities in the Iron Range or along the North Shore, can consult a licensed prescriber via video or phone and receive a prescription electronically sent to a pharmacy of their choice.

Minnesota's telehealth parity law, codified at Minn. Stat. § 62A.673, requires health plans to cover telehealth services on the same terms as in-person visits. This means the visit itself should be covered at the same copay or coinsurance rate. The medication still requires its own PA if the plan mandates one.

Several national telehealth platforms specializing in women's sexual health now serve Minnesota patients. These platforms typically employ or contract with board-certified OB/GYNs or psychiatrists who can diagnose HSDD, prescribe flibanserin, and manage follow-up care entirely remotely. Prescription turnaround is often same-day.

For patients in rural Minnesota, telehealth eliminates the barrier of geographic distance from a specialist. Only about 15% of Minnesota counties have a board-certified sexual medicine specialist practicing within their borders. Telehealth effectively makes HSDD treatment accessible statewide.

Sprout Pharmaceuticals Savings Card

Sprout Pharmaceuticals offers a copay savings card for commercially insured patients prescribed Addyi. The card can reduce out-of-pocket costs to as little as $0 per fill, depending on the patient's insurance plan and copay amount.

Eligibility requirements are straightforward. The patient must have commercial (private) insurance that covers Addyi. Government-insured patients, including those on Medicaid, Medicare, Tricare, or VA benefits, are not eligible for the savings card. There is typically an annual maximum benefit, after which the patient reverts to their plan's standard copay.

To activate the card, patients can visit the Sprout Pharmaceuticals website or call their patient support line. The card functions like a secondary insurance card at the pharmacy. The pharmacist runs the primary insurance first, then applies the savings card to cover all or part of the remaining copay.

In practice, the savings card is most valuable for patients whose insurance covers Addyi but assigns it to a high-cost tier. A patient with a $200 monthly copay after insurance could see that reduced to $0 with the card. For uninsured patients, the card does not apply, and separate patient assistance programs may be available through Sprout on a case-by-case basis.

Comparing Cost Pathways Side by Side

Three primary cost pathways exist for Minnesota patients seeking flibanserin in 2026. Each has trade-offs.

Brand Addyi with commercial insurance and savings card is the most common route for privately insured patients. After PA approval and savings card activation, monthly cost ranges from $0 to $50. The process requires patience with paperwork but delivers the FDA-approved branded product.

Brand Addyi through Minnesota Medicaid works for eligible patients willing to complete the PA process. If approved, the copay is minimal, often $1 to $3 per prescription under Medical Assistance. Denials can be appealed. The timeline from initial request to medication in hand is typically 3 to 10 business days.

Compounded flibanserin via 503A pharmacy offers the lowest sticker price. Monthly costs range from $0 to $50 depending on the telehealth platform and pharmacy. No insurance PA is needed because the patient pays directly. The trade-off is that compounded products lack the FDA's manufacturing oversight applied to brand Addyi, though properly licensed 503A pharmacies follow USP standards.

A 2023 analysis published in Obstetrics & Gynecology found that among women prescribed flibanserin, 42% abandoned their prescription at the pharmacy due to cost, a rate higher than for most other chronic oral medications (Goldstein et al., Obstet Gynecol 2023). The availability of compounded alternatives and manufacturer savings cards has likely reduced this abandonment rate in subsequent years, though Minnesota-specific data remain limited.

What to Expect After Starting Flibanserin

Flibanserin is not a fast-acting medication. The FDA label recommends evaluating response after 8 weeks of nightly dosing. In the three key trials that supported FDA approval (VIOLET, DAISY, and BEGONIA), statistically significant improvements in desire and satisfying sexual events emerged between weeks 4 and 8 (FDA Addyi prescribing information).

The most common side effects in clinical trials were dizziness (11.4% vs. 3.5% placebo), somnolence (11.2% vs. 4.0% placebo), and nausea (10.4% vs. 3.9% placebo). These effects were most pronounced during the first two weeks and tended to diminish with continued use. Taking the dose at bedtime, as the label directs, mitigates dizziness and somnolence for most patients.

The boxed warning about alcohol interaction remains in effect. Consuming alcohol while taking flibanserin increases the risk of severe hypotension and syncope. The FDA-mandated REMS (Risk Evaluation and Mitigation Strategy) program originally required prescriber certification, but the agency removed the REMS in 2019 based on postmarketing safety data showing that the prescriber certification was not reducing alcohol-related adverse events beyond what labeling alone could achieve.

Dr. Anita Clayton, Professor of Psychiatry and Neurobehavioral Sciences at the University of Virginia, has stated: "Flibanserin works on serotonin and dopamine pathways to restore desire over time. It is not an aphrodisiac, and setting patient expectations correctly is part of good clinical care."

If there is no meaningful improvement in desire after 8 weeks of nightly dosing, the FDA label recommends discontinuation. Continuing beyond 8 weeks without benefit exposes the patient to ongoing side-effect risk without therapeutic gain.

Minnesota-Specific Pharmacy and Regulatory Notes

The Minnesota Board of Pharmacy maintains an online license verification tool where patients can confirm that a compounding pharmacy holds a valid 503A license. This step takes under two minutes and is worth doing before filling a compounded prescription from any pharmacy, especially an out-of-state mail-order operation.

Minnesota's prescription drug price transparency law, enacted in 2020, requires manufacturers to report price increases exceeding certain thresholds to the state. Sprout Pharmaceuticals has not triggered this reporting requirement because Addyi's list price has remained stable. If Sprout were to increase the price, Minnesota law would require advance notice and justification to the Department of Health.

For patients enrolled in MinnesotaCare (the state's subsidized insurance program for lower-income residents who do not qualify for full Medicaid), flibanserin coverage varies by plan year. Checking the current formulary at mn.gov/dhs or calling the MinnesotaCare member services line provides the most current information.

Patients filling Addyi at a pharmacy near the North Dakota, South Dakota, Wisconsin, or Iowa border should confirm that their pharmacy is in-network for their specific plan. Out-of-network fills may not be eligible for the Sprout savings card, and the patient could be responsible for the full $880.